ALCHEMIA AWAITS APPROVAL

Written on the 6 April 2011

ALCHEMIA AWAITS APPROVAL

CONTINUING progress with its programs has not eased shareholder frustration with drug developer Alchemia due delays by the US Food and Drug Administration (FDA) to approve its new antithrombotic fondaparinux.

The company posted a net loss after tax of $6.7 million for the December half, with total income for the period of $784 000.

Managing director Pete Smith (pictured) says the company is working on other projects as it awaits approval of the injectible version of fondaparinux.

“We signed a partnership with US-based Emisphere Technologies to develop an oral formulation of the compound utilizing Eligen technology,” he says.

“This broad based drug delivery platform is designed to enhance the oral bioavailability of the drug without altering its chemical form or biological activity. An oral formulation of fondaparinux will expand the profile of the drug and potentially increase its market potential.”

The company has been preparing for the Phase 3 trial design for HA-Irinotecan, which will be initiated after approval for fondaparinux.

“The $25 million trial will be conducted in 60 sites in at least six countries and in July 2010 was adopted by the National Cancer Research network in the UK,” says Smith.

“This organisation provides the National Health Service in England, with the infrastructure to support cancer clinical trials and works closely with the cancer centers to provide clinical trial support across the UK.”

Over the past 12 months, the company has also spent significant time advancing its oncology platform, featuring HyACT tumor targeting technology.

TOP PUBLIC COMPANIES PROFILE: No. 39 Alchemia (ACL)

Managing director: Dr Pete Smith
Market Cap: $143 million
Revenue ’10: $629 000
Loss ’10: $8.8 million
Staff: 12
Established: 1995


Latest News

GUVERA ESCAPES WIND-UP ORDER

GUVERA has avoided being wound up after a claim for a $1.78 million debt by Kwong Properties was dismissed at the ...

CONSUMERS PESSIMISTIC ENTERING 2017

CONSUMER confidence remains at its weakest point since April 2016, according to the latest Westpac Melbourne Institut...

WESFARMERS' COAL BUSINESS ON FIRE

WESFARMERS (ASX: WES) has lifted its first-half profit guidance due to surging coal prices and higher than expected c...

SIXTH CONSECUTIVE RECORD PROFIT FOR AP EAGERS

AP EAGERS (ASX: APE) will beat guidance with its sixth-consecutive record profit when it reports its full year result...

Related News

CONSUMERS PESSIMISTIC ENTERING 2017

CONSUMER confidence remains at its weakest point since April 2016, according to the latest Westpac Melbourne Institut...

RISE OF STARTUP SUPPORT PROGRAMS NOT AS ROSY AT IT SEEMS

ENTREPRENEURIAL cultivation companies in Australia are appearing quickly, but questions have been raised about whe...

SMES TAKE RETAIL MARKET SHARE AS CONSUMERS CHOOSE PERSONALISATION

IN a battle for the hearts and wallets of Australian consumers, it appears that small and medium retail businesses...

KNOWLEDGE WORKERS AMONG MOST SOUGHT AFTER IN 2017

BUSINESSES searching for efficiencies and improved systems are in search of knowledge workers early this year, say...

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter